Bezuclastinib for advanced systemic mastocytosis
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study provides access to bezuclastinib, an oral medication, for people with advanced systemic mastocytosis whose current treatment isn't working well enough. The goal is to see if it can help control the disease when other options have not been effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with advanced systemic mastocytosis (a rare blood disorder where too many mast cells build up in the body).
- Your current treatment is not controlling the disease well enough.
- You are not already in another clinical trial for bezuclastinib, and you have not stopped taking it in the past due to side effects.
- You are not pregnant or breastfeeding.
- You have no other serious health conditions that would make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
This study looks at people with a slow-growing type of mast cell disease called indolent systemic mastocytosis. The goal is to better understand the condition and how to manage it, using your genetic information to guide future care.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
Hear when a new Systemic Mastocytoses, Indolent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.